Predicting which glioblastoma patients may benefit from drug treatment

29 junio 2015

Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers who conducted one of those clinical trials, believe they know why dasatinib failed — and what to do about it.